Physical complications in early clozapine treatment: A case report and implications for safe monitoring

Therapeutic Advances in Psychopharmacology

Volumn 1, Issue 1, 2011, Pages 25-29

  Patel, Sachin S ^a   Allin, Matthew P G ^b  

^a BETHLEM ROYAL HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

clozapine; diabetes; monitoring; pneumonia; schizoaffective disorder; schizophrenia

Indexed keywords

EID: 84997868289     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125311398284     Document Type: Article

References (17)

1. American Diabetes Association. (2004) Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes (consensus statement). Diabetes Care 27: 596–601.
2. Berk M. Fitzsimons J. Lambert T. Pantelis C. Kulkarni J. Castle D. et al. (2007) Monitoring the safe use of clozapine. A consensus view from Victoria, Australia. CNS Drugs 21: 117–127.
3. Hasnain M. Fredrickson S.K. Vieweg W.V. Pandurangi A.K. (2010) Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep 10: 209–216.
4. Henderson D.C. Nguyen D.D. Copeland P.M. Hayden D.L. Borba C.P. Louie P.M. et al. (2005) Clozapine, diabetes mellitus, hyperlipidaemia and cardiovascular risks and mortality: Results of a 10 year naturalistic study. J Clin Psychiatry 66: 1116–1121.
5. Hinkes R. Quesada T.V. Currier M.B. Gonzalez-Blanco M. (1996) Aspiration pneumonia possibly secondary to clozapine-induced sialorrhea. J Clin Pharmacol 16: 462–463.
6. Holt R.I.G. Bushe C. Citrome L. (2005) Diabetes and schizophrenia 2005: Are we any closer to understanding the link? J Psychopharm 19: 56–65.
7. Howes O.D. Bhatnagar A. Gaughran F.P. Amiel S.A. Murray R.M. Pilowsky L.S. (2004) A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 161: 361–363.
8. Knol W van Marum R.J Jansen P.A.F Souverein P.C Schobben A.F.A.M Egberts A.C.G. (2008) Antipsychotic drug use and risk of pneumonia in elderly people. JAGS 56: 661–666.
9. Koller E. Schneider B. Bennett K. Dubitsky G. (2001) Clozapine associated diabetes. Am J Med 111: 716–723.
10. Maddalena A.S. Fox M. Hofmann M. Hock C. (2004) Esophageal dysfunction on psychotropic medication. A case report and literature review. Pharmacopsychiatry 37: 134–138.
11. National Institute for Health and Clinical Excellence. (2009) Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). Available at: www.nice.org.uk/CG82.
12. Newcomer J.W. (2005) Second generation (atypical) antipsychotics and metabolic effects. A comprehensive literature review. CNS Drugs 19(Suppl. 1): 1–93.
13. Nihalani N.D. Tu X. Lamberti J.S. Olson D. Olivares T. Costea G.O. et al. (2007) Diabetic ketoacidosis among patients receiving clozapine: A case series and review of socio-demographic risk factors. Ann Clin Psychiatry 19: 105–112.
14. Taylor D. Paton C. Kapur S. (2009a) The Maudsley Prescribing Guidelines. 10th ed. Informa Healthcare, London.
15. Taylor D.M. Douglas-Hall P. Olofinjana B. Whiskey E. Thomas A. (2009b) Reasons for discontinuing clozapine: matched, case–control comparison with risperidone long acting injection. Br J Psychiatry 194: 165–167.
16. Tovey E. Rampes H. Livingstone C. (2005) Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice. J Psychopharmacol 19: 207–210.
17. Trifirò G. Gambassi G. Sen E.F. Caputi A.P. Bagnardi V. Brea J. et al. (2010) Association of community-acquired pneumonia with antipsychotic drug use in elderly patients. A nested case–control study. Ann Intern Med 152: 418–425.